NO317396B1 - Retard-tablett inneholdende Diclofenac-Na som virkestoff og metylhydroksypropylcellulose som retardasjonsmiddel, samt vanlige hjelpestoffer - Google Patents
Retard-tablett inneholdende Diclofenac-Na som virkestoff og metylhydroksypropylcellulose som retardasjonsmiddel, samt vanlige hjelpestoffer Download PDFInfo
- Publication number
- NO317396B1 NO317396B1 NO19963796A NO963796A NO317396B1 NO 317396 B1 NO317396 B1 NO 317396B1 NO 19963796 A NO19963796 A NO 19963796A NO 963796 A NO963796 A NO 963796A NO 317396 B1 NO317396 B1 NO 317396B1
- Authority
- NO
- Norway
- Prior art keywords
- tablet
- diclofenac
- retard
- methylhydroxypropylcellulose
- active ingredient
- Prior art date
Links
- -1 methyl hydroxypropyl Chemical group 0.000 title claims description 8
- 239000004480 active ingredient Substances 0.000 title claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 title claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 title description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 title description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 title description 2
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000011149 active material Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 description 34
- 230000036470 plasma concentration Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4408326A DE4408326A1 (de) | 1994-03-11 | 1994-03-11 | Retardtablette mit einem Gehalt an Diclofenac-Na |
| PCT/EP1995/000928 WO1995024188A1 (de) | 1994-03-11 | 1995-03-13 | Retardtablette mit einem gehalt an diclofenac-na |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963796D0 NO963796D0 (no) | 1996-09-10 |
| NO963796L NO963796L (no) | 1996-11-06 |
| NO317396B1 true NO317396B1 (no) | 2004-10-25 |
Family
ID=6512563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963796A NO317396B1 (no) | 1994-03-11 | 1996-09-10 | Retard-tablett inneholdende Diclofenac-Na som virkestoff og metylhydroksypropylcellulose som retardasjonsmiddel, samt vanlige hjelpestoffer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5874107A (da) |
| EP (1) | EP0749304B9 (da) |
| JP (1) | JPH09509953A (da) |
| AT (1) | ATE173399T1 (da) |
| AU (1) | AU692534B2 (da) |
| CA (1) | CA2185242C (da) |
| DE (2) | DE4408326A1 (da) |
| DK (1) | DK0749304T4 (da) |
| ES (1) | ES2126265T5 (da) |
| FI (1) | FI118294B (da) |
| GR (1) | GR3029278T3 (da) |
| NO (1) | NO317396B1 (da) |
| PL (1) | PL177607B1 (da) |
| WO (1) | WO1995024188A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| AU3860797A (en) * | 1997-07-16 | 1999-02-10 | Antrin Research Limited | Pharmaceutical formulations for oral administration |
| JP4565456B2 (ja) * | 1999-11-02 | 2010-10-20 | 塩野義製薬株式会社 | 着色顆粒の色素定着法 |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| JP2005526079A (ja) * | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス， インコーポレイテッド | 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤 |
| US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| AU2004207578B2 (en) * | 2003-01-28 | 2007-06-28 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| US8107531B2 (en) * | 2003-09-07 | 2012-01-31 | Microsoft Corporation | Signaling and repeat padding for skip frames |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5236713A (en) * | 1987-10-21 | 1993-08-17 | Teikoku Seiyaku Kabushiki Kaisha | Preparation for intermittently releasing active agent applicable to oral cavity |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
-
1994
- 1994-03-11 DE DE4408326A patent/DE4408326A1/de not_active Ceased
-
1995
- 1995-03-13 JP JP7523249A patent/JPH09509953A/ja active Pending
- 1995-03-13 DE DE59504270T patent/DE59504270D1/de not_active Expired - Lifetime
- 1995-03-13 AT AT95913097T patent/ATE173399T1/de active
- 1995-03-13 DK DK95913097T patent/DK0749304T4/da active
- 1995-03-13 US US08/714,063 patent/US5874107A/en not_active Expired - Lifetime
- 1995-03-13 PL PL95316196A patent/PL177607B1/pl not_active IP Right Cessation
- 1995-03-13 ES ES95913097T patent/ES2126265T5/es not_active Expired - Lifetime
- 1995-03-13 EP EP95913097A patent/EP0749304B9/de not_active Expired - Lifetime
- 1995-03-13 CA CA002185242A patent/CA2185242C/en not_active Expired - Fee Related
- 1995-03-13 AU AU20695/95A patent/AU692534B2/en not_active Ceased
- 1995-03-13 WO PCT/EP1995/000928 patent/WO1995024188A1/de active IP Right Grant
-
1996
- 1996-09-10 FI FI963567A patent/FI118294B/fi not_active IP Right Cessation
- 1996-09-10 NO NO19963796A patent/NO317396B1/no not_active IP Right Cessation
-
1999
- 1999-02-03 GR GR990400358T patent/GR3029278T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0749304B9 (de) | 2006-03-08 |
| EP0749304B2 (de) | 2004-03-03 |
| AU692534B2 (en) | 1998-06-11 |
| WO1995024188A1 (de) | 1995-09-14 |
| CA2185242A1 (en) | 1995-09-14 |
| ES2126265T5 (es) | 2004-10-16 |
| PL316196A1 (en) | 1996-12-23 |
| NO963796D0 (no) | 1996-09-10 |
| FI963567A0 (fi) | 1996-09-10 |
| DK0749304T4 (da) | 2004-03-29 |
| GR3029278T3 (en) | 1999-05-28 |
| NO963796L (no) | 1996-11-06 |
| DE4408326A1 (de) | 1995-09-14 |
| US5874107A (en) | 1999-02-23 |
| ES2126265T3 (es) | 1999-03-16 |
| FI963567A (fi) | 1996-09-10 |
| CA2185242C (en) | 2004-11-23 |
| EP0749304B1 (de) | 1998-11-18 |
| DK0749304T3 (da) | 1999-08-02 |
| ATE173399T1 (de) | 1998-12-15 |
| DE59504270D1 (de) | 1998-12-24 |
| AU2069595A (en) | 1995-09-25 |
| EP0749304A1 (de) | 1996-12-27 |
| PL177607B1 (pl) | 1999-12-31 |
| FI118294B (fi) | 2007-09-28 |
| JPH09509953A (ja) | 1997-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4832957A (en) | Controlled release combination of carbidopa/levodopa | |
| US6476006B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| US20070104786A1 (en) | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate | |
| US20050026871A1 (en) | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative | |
| FI101040B (fi) | Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi | |
| RU2533230C2 (ru) | Фармацевтические композиции, содержащие производные бисфосфоната и высокие дозы холекальциферола | |
| JPH05255081A (ja) | 持続性放出甲状腺作用性組成物 | |
| KR20010042473A (ko) | 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법 | |
| TW508242B (en) | Pharmaceutical composition comprising paracetamol | |
| HU227003B1 (en) | Rapid onset formulation comprising enterically coated pyridoxine hydrocloride and doxylamine succinate | |
| NO317396B1 (no) | Retard-tablett inneholdende Diclofenac-Na som virkestoff og metylhydroksypropylcellulose som retardasjonsmiddel, samt vanlige hjelpestoffer | |
| WO2010008976A2 (en) | Combined calcium, magnesium and vitamin d supplements | |
| ZA200603421B (en) | A controlled release pharmaceutical composition and a process for preparing the same | |
| WO2011155728A2 (ko) | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 | |
| IL106743A (en) | Tablets with enhanced bioavailability of claudonic acid | |
| US5035898A (en) | Potassium/magnesium supplement | |
| US5773429A (en) | Drug combination for treating calcium loss | |
| KR20050035250A (ko) | 바이시파딘 포뮬레이션 | |
| RU2336076C2 (ru) | Пероральное лекарственное средство для восполнения дефицита магния в организме | |
| CA2893480C (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
| RU2209087C2 (ru) | Агент для пролонгирования действия лекарственного препарата и лекарственная композиция на его основе | |
| KR20010099827A (ko) | 새로운 제약 조성물 및 그것의 제조방법 | |
| US4522818A (en) | Diuretic/antihypertensive compositions | |
| CZ20031589A3 (cs) | Farmaceutický prostředek s obsahem gepironu | |
| JPH0248525A (ja) | 消化性潰瘍治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |